tiprankstipranks
Trending News
More News >

Biodexa announces activation of first clinical study site for Serenta trial

Biodexa Pharmaceuticals (BDRX) announces the activation of the first clinical study site for its Serenta trial in patients with familial adenomatous polyposis, FAP. The trial, which is now enrolling, represents a significant milestone in the development of a potential new treatment option for FAP. The Serenta trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of eRapa in individuals diagnosed with FAP. The first site, in the US, is now open and actively screening eligible participants.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1